

CLINUVEL PHARMACEUTICALS LTD (ASX: CUV)



Clinuvel is an Australian biopharmaceutical company focused on developing its leading photoprotective drug afamelanotide (CUV1647), for a range of UV and light related skin disorders. Clinuvel is headquartered in Melbourne with operational offices in San Francisco and Zürich.

Facts	ASX Listed	2001	
	Shares on Issue	303,148,665	
	Options (unlisted)	34,349,022	
	Top 20 own	65%	
	52 weeks price range	\$0.21 - \$0.60	
	Employees	20	
People	Brenda Shanahan	Chair	
	Dr Philippe Wolgen	CEO, Director	
	Dr Helmer P.K. Agersborg	Chief Scientific Officer, Director	
	Stanley McLiesh	Non-Executive Director	
	Dr Roger Aston	Non-Executive Director	
	Jack Wood	Non-Executive Director	
	Dr Dennis Wright	Manager, Clinical and Regulatory Affairs	
	Darren Keamy	CFO	
Head office contact	Colin Mackie	Head of Corporate Development	
	Phone	+61 3 9660 4900	
	Fax	+61 3 9660 4999	
	Email (general)	mail@clinuvel.com	
	Email (investors)	investorrelations@clinuvel.com	
	Postal address	Clinuvel Pharmaceuticals Ltd Level 11, 330 Collins St Melbourne, Vic 3000 Australia	
	US office contact	Phone	+1 415 772 9100
Fax		+1 415 772 0919	
Postal address		Clinuvel Inc Suite 560, 353 Sacramento St San Francisco CA 94111 United States of America	
European office contact		Phone	+41 44 253 75 00
	Postal Address	Clinuvel AG Hauserstrasse 14 8032 Zürich Switzerland	
	Australian Share registry	Name	Computershare
		Phone	+61 3 9415 4000
Online		www.computershare.com.au	
Postal address		Yarra Falls, 452 Johnson St Abbotsford, Vic 3067 Australia	
US ADR Registrar and Transfer Agent	Clinuvel ASX Symbol	CUV	
	Name	Bank of New York Mellon	
	Phone	+61 3 9640 3907	
	Online	www.bankofny.com	
	Postal Address	350 Collins St Melbourne, Vic 3000 Australia	
German Xetra Sponsoring Broker	Clinuvel ADR Symbol	CLVLY	
	Name	Close Brothers Seydler AG	
	Phone	+49 0 69 9 20 54 0	
	Online	www.cbseydler.com	
	Postal Address	Neue Rothofstraße 17 D 60313 Frankfurt am Main Germany	
	Clinuvel Symbol	UR9	

About Clinuvel Pharmaceuticals Limited

Clinuvel Pharmaceuticals Limited (ASX:**CUV**, XETRA/DAX:**UR9**, ADR:**CUVLY**) is an Australian biopharmaceutical company developing its photoprotective drug afamelanotide as a preventative treatment for a range of UV-related skin disorders as well as in cancer related treatments.

The five indications are:

Indication	Description	Clinical Trial Status
Erythropoietic Protoporphyrin (EPP)	Absolute sun intolerance	Phase III trials began June 2007
Polymorphic Light Eruption (PLE / PMLE)	Sun poisoning	Phase III trials began May 2007
Squamous Cell Carcinoma (SCC) and Actinic Keratosis (AK) in Organ Transplant Patients (OTP)	Non-melanoma skin cancers / precursor to skin cancers	Phase II trials began November 2007
Solar Urticaria (SU)	Acute anaphylactic reaction to sun	Phase II trials began June 2008
Phototoxicity associated with Photodynamic Therapy (PDT)	Photosensitivity associated with cancer treatment	Phase II trials began September 2008

Phase I and II human clinical trials using afamelanotide have demonstrated that the drug is well tolerated and no significant safety concerns have been identified to date.

Following successful conclusion of the development program, Clinuvel will work closely with global regulators to facilitate marketing approval of afamelanotide.

Clinical Trial Summary

Medical indications	Phase I	Phase II	Phase III	Marketing Authorization Application	Drug Registration
EPP sun intolerance				2009	
PLE sun poisoning				2010	
AK precursor to skin cancer				2010-2011	
SU anaphylactic reaction to sun					
PDT photo-sensitivity with cancer treatment					

For more information contact:

Colin Mackie
Head of Corporate Development
Clinuvel Pharmaceuticals Limited
Tel: +61 3 9660 4900
investorrelations@clinuvel.com

Clinuvel is an Australian biopharmaceutical company focussed on developing its leading drug candidate, afamelanotide, for a range of UV-related skin disorders resulting from exposure of the skin to harmful UV radiation. Pharmaceutical research and development involves long lead times and significant risks. Therefore, while all reasonable efforts have been made by Clinuvel to ensure that there is a reasonable basis for all statements made in this document that relate to prospective events or developments (forward-looking statements), investors should note the following:

- actual results may and often will differ materially from these forward-looking statements;
- no assurances can be given by Clinuvel that any stated objectives, outcomes or timeframes in respect of its development programme for afamelanotide can or will be achieved;
- no assurances can be given by Clinuvel that, even if its development program for afamelanotide is successful, it will obtain regulatory approval for its pharmaceutical products or that such products, if approved for use, will be successful in the market place.